Subgroup analyses revealed important differences based on comparator drugs: GLP-1RAs demonstrated greater effectiveness than SGLT2 inhibitors in preventing MALOs (IRR: 0.93, 95%CI: 0.87-0.99, P = 0.043), than DPP-4 inhibitors in preventing hepatic decompensation events (IRR: 0.74, 95%CI: 0.66-0.83, P = 0.003), and than insulin therapy in averting HCC development (IRR: 0.32, 95%CI: 0.13-0.80, P = 0.033) [64]
Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, et al
What You Can Do Now to Prepare Even if your goal is to eventually use retatrutide, there is no reason to delay taking action on your weight loss and metabolic health: Start with a proven medication
However, not everyone will be eligible
Semaglutide is roughly 18 times larger